[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353489-105":59,"doc-detail-353489-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-status-of-research-on-losartan-in-tumour-therapy","Current Status of Research on Losartan in Tumour Therapy","","Losartan, a widely prescribed antihypertensive agent, is increasingly explored as an adjuvant in cancer therapy due to affordability, a well-established safety profile, and pleiotropic actions. Preclinical studies indicate that losartan modulates the tumour microenvironment (TME) by suppressing TGF-β signalling, lowering stromal stiffness, and improving vascular perfusion, thereby enhancing chemotherapy delivery and function, including when paired with nanocarriers. The drug also shows anti-tumour effects across multiple solid-tumour models through AT1R blockade.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-status-of-research-on-losartan-in-tumour-therapy/353489/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-status-of-research-on-losartan-in-tumour-therapy/353489.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is losartan being investigated as an adjuvant for tumour therapy?","Question",{"text":112,"@type":113},"Losartan has an established safety profile and pleiotropic effects, and preclinical evidence suggests it can modulate the tumour microenvironment to support anti-cancer activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does losartan alter the tumour microenvironment (TME)?",{"text":117,"@type":113},"By inhibiting TGF-β signalling, reducing stromal stiffness, and improving vascular perfusion, it enhances delivery and efficacy of chemotherapeutic agents, with potential amplification via nanocarriers.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main barriers to translating preclinical findings into clinical practice?",{"text":121,"@type":113},"Clinical validation remains limited to early-phase trials, with unresolved questions about variable efficacy across cancer types and key parameters such as optimal patient selection, dosing, sequencing, and long-term safety.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353489,1790586795,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Journal of Cellular and Molecular Medicine   \n REVIEW  OPEN ACCESS   \nCurrent Status of Research on Losartan in Tumour Therapy  \nHan Wang | Shuang Yuan | Hongjing Wang   \nDepartment of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of the Ministry of Education, West  \nChina Second University Hospital, Sichuan University, Chengdu, China Correspondence: Hongjing Wang ([whjscdx@163.com](whjscdx@163.com))  \nReceived: 9 February 2025 | Revised: 9 October 2025 | Accepted: 30 November 2025  \nKeywords: AT1R | cancer therapy | ECM remodelling | immune modulation | losartan | matrix stiffness | nanocarriers | RAS | TME | vascular normalisation  \nABSTRACT  \nLosartan, a widely prescribed antihypertensive agent, has attracted growing interest as a potential adjuvant in cancer therapy due to its affordability, established safety profile and pleiotropic effects. Emerging preclinical evidence demonstrates that losartan can effectively modulate the tumour microenvironment (TME) by inhibiting transforming growth factor-β (TGF-β) signalling, reducing stromal stiffness and improving vascular perfusion. These changes are shown to enhance the delivery and efficacy of chemotherapeutic agents, an effect potentially amplified when combined with nanocarriers by augmenting the enhanced permeability and retention effect. Beyond TME remodelling, losartan has demonstrated anti-tumour activity across various preclinical models, including those of pancreatic, breast and colorectal cancers. Mechanistically, angiotensin II type 1 receptor (AT1R) blockade is reported to modulate key downstream oncogenic pathways, including PI3K/AKT and YAP/TAZ, and to promote vascular normalisation via mechanisms that may include VEGF downregulation, thereby alleviating hypoxia and improving radiotherapy response. Furthermore, evidence suggests losartan remodels the tumour immune landscape by promoting CD8+ T and natural killer (NK) cell infiltration, reprogramming tumour-associated macrophages (TAMs) and suppressing immunosuppressive cytokines. It also appears to inhibit epithelial-mesenchymal transition (EMT) and metastasis-related pathways, including CXCR4/SDF-1α and matrix metalloproteinases (MMPs) . These multifaceted mechanisms highlight its potential as a therapeutic adjuvant capable of overcoming stromal barriers, mitigating immune evasion and limiting metastatic dissemination. However, the translation of these compelling preclinical findings into clinical practice remains a major challenge. The promising preclinical data are tempered by variable efficacy across cancer types, a nascent clinical evidence base and unresolved questions regarding optimal patient selection and dosing. Clinical validation is still nascent, predominantly limited to early-phase trials and critical parameters such as optimal dosing, treatment sequencing and long-term safety in oncology patients await rigorous definition. This review synthesises the current mechanistic and translational research on losartan in solid tumours, aiming to clarify its anti-cancer properties, explore its synergy with nano-and immune-therapeutics, critically assess the associated challenges and identify key gaps and future directions for clinical application.  \n[Trial Registration:](Trial Registration: ClinicalTrials.gov)[ ClinicalTrials.gov](Trial Registration: ClinicalTrials.gov) identifier: NCT01821729 and NCT03563248  \n1 | Introduction  \nIn 2022, approximately 4.82 million new cancer cases were projected in China, corresponding to an age-standardised incidence rate of 208.58 per 100,000 individuals [1] . These statistics  \nunderscore the growing global burden of cancer and the urgent need for more effective therapeutic strategies. Despite considerable advances in oncology, conventional treatments—such as surgery, chemotherapy and radiotherapy—remain the primary therapeutic options for most tumours [2–5]. However, limitations  \nThis is an open access article unde","cbCaikk3OdQ4OdLq","https://ap.wps.com/l/cbCaikk3OdQ4OdLq","pdf",3763051,18,"English","# Introduction\n## Renin–angiotensin system and tumour progression\n## Angiotensin II receptors in oncology\n# Clinical translation challenges","[{\"question\":\"Why is losartan being investigated as an adjuvant for tumour therapy?\",\"answer\":\"Losartan has an established safety profile and pleiotropic effects, and preclinical evidence suggests it can modulate the tumour microenvironment to support anti-cancer activity.\"},{\"question\":\"How does losartan alter the tumour microenvironment (TME)?\",\"answer\":\"By inhibiting TGF-β signalling, reducing stromal stiffness, and improving vascular perfusion, it enhances delivery and efficacy of chemotherapeutic agents, with potential amplification via nanocarriers.\"},{\"question\":\"What are the main barriers to translating preclinical findings into clinical practice?\",\"answer\":\"Clinical validation remains limited to early-phase trials, with unresolved questions about variable efficacy across cancer types and key parameters such as optimal patient selection, dosing, sequencing, and long-term safety.\"}]","Current Status of Research on Losartan in Tumour Therapy | PDF",1790105739,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3589a402c27006453089593ce5e1840d.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b80b68747ae2f71aee2d82b307274058.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3340963e9debfa6e7c20dd2e626d729.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a90c3773dd6ab84570ebdc0cab191b6.webp",980,1287]